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Tumor cells exhibit distinct metabolic phenotypes that
are essential for them to sustain higher proliferative
rates and resist some cell death signals, altering the flux
along key metabolic pathways, such as glycolysis and
glutaminolysis. When used as a translational research
tool, metabolomics enables the discrimination of distinct
metabolic profiles and metabolite markers noninvasively
in vivo that correlate to pathological stages and different
responses to treatment modalities. Cancer metabolomics
research aims at evaluating and predicting pathophysio-
logical changes of cancer patients by investigating meta-
bolic signatures in body fluids or tissues, which are
influenced by genetics, epigenetics, environmental expo-
sures, diet, and behavior. A particular advantage of
metabolomics is that it represents a top-down tactic in
that all of the molecules detected are interrogated, pro-
viding a global picture of dynamic metabolic changes
involving key markers and pathways that were not
already associated with carcinogenesis.
We describe here our studies with mass spectrometry
based metabolomic profiling of serum, urine and tissue
samples from colorectal cancer (CRC) patients. The meta-
bolic profile of CRC involves several significantly altered
pathways, including increased glycolysis and an impaired
TCA cycle, glutaminolysis, down-regulated urea cycle, dys-
regulated tryptophan, nucleotides, carnitine, and choline
metabolism, and an significantly altered gut microbial-host
co-metabolism. Our experimental results highlight the
potential for the metabolomic approach to have a multi-
tude of uses in oncology, including the early detection and
diagnosis of cancer and as both a predictive and pharma-
codynamic marker of therapeutic effect.
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